9 Einträge gefunden

1. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

   1. Weisel, Katja
   2. Nooka, Ajay K
   3. Terpos, Evangelos
   4. Spencer, Andrew
   5. Goldschmidt, Hartmut
   6. Dirnberger, Franziska
   7. DeCosta, Lucy

   2022 - Forschungsinformationssystem des UKE
2. Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma

   1. Hájek, Roman
   2. Minařík, Jiří
   3. Straub, Jan
   4. Pour, Luděk
   5. Jungova, Alexandra
   6. Berdeja, Jesus G
   7. Boccadoro, Mario

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

   1. Avet-Loiseau, Hervé
   2. San-Miguel, Jesus
   3. Casneuf, Tineke
   4. Iida, Shinsuke
   5. Lonial, Sagar
   6. Usmani, Saad Z
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

   1. Quach, Hang
   2. Nooka, Ajay
   3. Samoylova, Olga
   4. Venner, Christopher P
   5. Kim, Kihyun
   6. Facon, Thierry
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

   1. Mateos, Maria-Victoria
   2. Spencer, Andrew
   3. Nooka, Ajay K
   4. Pour, Ludek
   5. Weisel, Katja
   6. Cavo, Michele
   7. Laubach, Jacob P

   2020 - Forschungsinformationssystem des UKE
6. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

   1. Weisel, Katja
   2. Spencer, Andrew
   3. Lentzsch, Suzanne
   4. Avet-Loiseau, Hervé
   5. Mark, Tomer M
   6. Spicka, Ivan
   7. Masszi, Tamas

   2020 - Forschungsinformationssystem des UKE
7. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

   1. Dimopoulos, Meletios A
   2. Jakubowiak, Andrzej J
   3. McCarthy, Philip L
   4. Orlowski, Robert Z
   5. Attal, Michel
   6. Bladé, Joan
   7. Goldschmidt, Hartmut

   2020 - Forschungsinformationssystem des UKE
8. How to manage neutropenia in multiple myeloma.

   1. Palumbo, Antonio
   2. Bladé, Jon
   3. Boccadoro, Mario
   4. Palladino, Carmela
   5. Davies, Faith
   6. Dimopoulos, Meletios
   7. Dmoszynska, Anna

   2012 - Forschungsinformationssystem des UKE
9. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

   1. Engelhardt, Monika
   2. Udi, Josefina
   3. Kleber, Martina
   4. Spencer, Andrew
   5. Rocci, Alberto
   6. Knop, Stefan
   7. Bruno, Benedetto

   2010 - Forschungsinformationssystem des UKE